BRIUMVI 25 mg/ml / 150 mg / 3 flacon(s)
7680695990027
CH-69599
L04AG14
07.15.0.
Reimbursement limitations:
BRIUMVI
BRIUMVI est remboursé pour le traitement des patients adultes atteints de formes actives de sclérose …
1 / 3
google
Details
- Product number
- 6959901
- CPT
- -
- Packaging group
- 3
- Unit
- Durchstechflasche(n)
- Composition
- ublituximabum 150 mg, natrii chloridum, natrii citras dihydricus, polysorbatum 80, acidum hydrochloridum concentratum, aqua ad iniectabile ad solutionem pro 6 ml corresp. natrium 31.57 mg.
Articles (1)
Briumvi 25 mg/ml, Konzentrat zur Herstellung einer Infusionslösung
Konzentrat
3
Official Swissmedic V2 data
Additional information from the official database
Official medical documents
Detailed composition
| Substance | Quantity | Type | Category |
|---|---|---|---|
|
(N/A)
|
150.0 MG | Substance | Wirkstoff (Principe actif) |
|
(N/A)
|
- | Substance | HNIDK |
|
(N/A)
|
- | Substance | HNIDK |
|
(N/A)
|
- | Substance | HNIDK |
|
(N/A)
|
- | Substance | HNIDK |
|
(N/A)
|
- | Substance | HNIDK |
|
(N/A)
|
31.57 MG | Substance | HBESI |
Reimbursement information
Public price
CHF 6879.05
Specialties list
Yes
Generic
No
Reimbursement limitation
SL addition date:
01/07/2025
Authorization holder
Neuraxpharm Switzerland AG
6330 Cham
Authorization information
- Swissmedic authorization number
- 69599
- Drug name
- Briumvi, Konzentrat zur Herstellung einer Infusionslösung
- Galenic form
- KOINF
- ATC Code
- L04AG14
- Authorization status
- Z
- Dispensation category
- A
- First authorization
- 06/02/2025
- Authorization expiration date
- 05/02/2030
- IT number
- 07.15.0.
- Domain
- Human medicine
Packaging details
- Description (FR)
- BRIUMVI 25 mg/ml / 150 mg / 3 flacon(s)
- Description (DE)
- BRIUMVI 25 mg/ml / 150 mg / 3 Durchstechflasche(n)
- Market launch
- 01/07/2025
- Narcotic (BTM)
- No